EZH2 and neoplasm: EZH2 (e.g., tazemetostat) and BET (e.g., JQ1) inhibitors reverse immune exclusion by reactivating silenced tumor-suppressor genes (e.g., HLA class I) and chemokine production (Li et al., 2025; de Vos et al., 2022).